2m 2m 2m 2m 2m 2m 2m
ABVC BIOPHARMA (ABVC)
NASDAQ
$1.28$0.00 (0.00%)
Price as of Jun 03, 2026 6:20 PM EDT- $36.7MMarket Cap
- -18.99%1-Year Change
- BiotechnologyIndustry
ABVC BIOPHARMA (ABVC)
$1.28$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 31,779 -93.76% | 509,589 +234.31% | 152,430 -84.28% | 969,783 +172.57% | |
Cost of Revenue | N/A N/A | 763 -99.75% | 302,037 +5.45% | 286,415 +5,531.44% | |
Gross Profit | 31,779 -93.75% | 508,826 +440.11% | -149,607 -121.89% | 683,368 +94.85% | |
Sales and Marketing Expense | 2.9M +27.68% | 2.3M -57.88% | 5.4M -11.52% | 6.1M +5.59% | |
Research and Development Expense | -121,085 -32.46% | -179,272 -83.13% | -1.1M -60.54% | -2.7M +168.32% | |
Depreciation and Amortization Expense | 25,330 -20.91% | 32,025 +12.25% | 28,531 +19.88% | 23,799 +98.44% | |
Total Operating Expenses | 7.2M +37.15% | 5.2M -35.36% | 8.1M -48.94% | 15.8M +31.03% | |
Operating Profit | -7.2M +51.98% | -4.7M -42.73% | -8.2M -45.64% | -15.1M +29.12% | |
Interest Income | 167,103 +91.29% | 87,358 -52.90% | 185,481 -1.24% | 187,817 +169.60% | |
Interest Expense | -340,240 -86.35% | -2.5M 0.00% | -2.5M +748.17% | -293,968 +29.38% | |
Interest Income and Expense and Net | -173,137 -92.80% | -2.4M +4.25% | -2.3M +2,074.13% | -106,151 -78.64% | |
Total Nonoperating Income and Expense | -1.2M +80.86% | -664,334 -72.75% | -2.4M +509.16% | -400,184 -180.82% | |
Income before Taxes | -8.4M +55.56% | -5.4M -49.60% | -10.7M -31.33% | -15.5M +38.39% | |
Income Taxes | 24,154 +121.85% | -110,539 -143.18% | 256,006 -67.91% | 797,778 -3.30% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | 709,961 N/A | |
Net Income | -7.9M +61.30% | -4.9M -53.38% | -10.5M -35.97% | -16.4M +36.45% | |
Net Income from Continuing Operations Applicable to Common | -8.4M +55.56% | -5.4M -49.60% | -10.7M -31.33% | -15.5M +38.39% | |
Basic EPS and Net Income | -0.39 -7.14% | -0.42 -82.72% | -2.43 +367.31% | -0.52 +1.96% | |
Diluted EPS and Net Income | -0.39 -7.14% | -0.42 -82.72% | -2.43 +367.31% | -0.52 +1.96% | |
Basic Weighted Average Shares | 20.1M +72.25% | 11.7M +169.26% | 4.3M -86.31% | 31.7M +26.39% | |
Diluted Weighted Average Shares | 20.1M +72.25% | 11.7M +169.26% | 4.3M -86.31% | 31.7M +26.39% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 681,480 +174.37% | 248,382 +312.90% | 60,155 -29.45% | 85,265 -98.54% | |
Short-Term Investments | 64,354 -0.59% | 64,736 -18.38% | 79,312 +4.64% | 75,797 -29.91% | |
Cash and Cash Equivalents and Short-Term Investments | 745,834 +138.20% | 313,118 +124.51% | 139,467 -13.41% | 161,062 -97.29% | |
Total Current Assets | 2.5M +14.75% | 2.2M +31.58% | 1.7M -44.54% | 3.0M -68.96% | |
Accumulated Depreciation | 3.4M +1.15% | 3.3M +0.20% | 3.3M +0.93% | 3.3M -0.30% | |
Property and Plant and Equipment and Net | 12.8M +2,411.39% | 511,088 -93.59% | 8.0M +1,288.43% | 573,978 +9.15% | |
Total Long-Term Assets | 116,966 -12.14% | 133,121 -98.33% | 8.0M +1,288.43% | 573,978 +9.15% | |
Total Assets | 21.1M +179.34% | 7.5M -47.97% | 14.5M +47.05% | 9.9M -28.05% | |
Income Taxes Payable | 11,964 N/A | N/A N/A | 112,946 N/A | N/A N/A | |
Total Short-Term Debt | 995,512 -44.39% | 1.8M +21.90% | 1.5M -41.94% | 2.5M +24.40% | |
Total Current Liabilities | 6.2M -6.00% | 6.6M +10.53% | 5.9M +1.94% | 5.8M +57.61% | |
Total Long-Term Debt | 399,975 -61.17% | 1.0M -62.81% | 2.8M +151.77% | 1.1M +69.23% | |
Total Long-Term Liabilities | 1.6M +575.97% | 236,807 -41.88% | 407,457 -48.54% | 791,827 -29.60% | |
Total Liabilities | 7.8M +13.92% | 6.8M +7.14% | 6.4M -3.89% | 6.6M +37.11% | |
Retained Earnings | -76.9M +11.47% | -68.9M +5.40% | -65.4M +19.15% | -54.9M +42.68% | |
Total Stockholders Equity | 11.1M +806.25% | 1.2M -85.38% | 8.4M +170.71% | 3.1M -64.96% | |
Total Shares Outstanding | 25.1M +80.65% | 13.9M +74.66% | 7.9M -75.83% | 32.9M +13.59% | |
Cash Flow | |||||
Cash from Operating Activities | -3.0M +65.07% | -1.8M -57.29% | -4.2M -42.75% | -7.4M -2.62% | |
Capital Expenditures | N/A N/A | N/A N/A | 21,201 -82.29% | 119,692 +583.84% | |
Cash from Investing Activities | -1.2M N/A | N/A N/A | -360,186 -79.08% | -1.7M +113.62% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 4.6M +134.15% | 2.0M -49.46% | 3.9M -2.37% | 4.0M -59.84% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | 99.85% +201.73% | -98.15% -239.28% | 70.47% -28.51% | |
Operating Margin | -22,503.10% +2,337.14% | -923.34% -82.87% | -5,390.35% +245.86% | -1,558.54% -52.63% | |
Return on Assets | -55.30% +24.25% | -44.51% -48.48% | -86.38% -38.06% | -139.45% +46.60% | |
Return on Equity | -128.20% +25.69% | -101.99% -44.29% | -183.09% -33.43% | -275.04% +40.33% | |
Revenue Growth | -93.76% -140.02% | 234.31% +378.01% | -84.28% -148.84% | 172.57% +755.08% | |
Current Ratio | 0.41 +22.08% | 0.33 +19.01% | 0.28 -45.59% | 0.51 -80.31% | |
Cash Ratio | 0.11 +191.82% | 0.04 +275.25% | 0.01 -31.29% | 0.01 -99.07% | |
Debt-to-Equity Ratio | 0.13 -94.54% | 2.30 +355.19% | 0.51 -56.86% | 1.17 +286.09% | |
Debt-to-Assets Ratio | 0.07 -82.27% | 0.37 +27.91% | 0.29 -20.61% | 0.37 +88.00% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow